Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5740210 | 0.98 | KDM4E (0.45) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL2089725 | 0.81 | LMNA (0.39) | HRH3CYP2D6HTTLMNAMAPT | |
| SCHEMBL6188610 | 0.81 | LMNA (0.47) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL471858 | 0.80 | KDM4E (0.60) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL3762622 | 0.80 | KDM4E (0.51) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL20410849 | 0.79 | KDM4E (0.49) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL6189074 | 0.79 | HRH3 (0.48) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL20410969 | 0.78 | KDM4E (0.51) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL6205697 | 0.78 | HRH3 (0.44) | KDM4EHRH3CYP2D6HTTLMNA | |
| SCHEMBL6050408 | 0.78 | HRH3 (0.44) | KDM4EHRH3CYP2D6HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | claimed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-7863450-B2 | Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2011-01-04 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| EP-1414802-B1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| CN-1630637-A | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | CN | disclosed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414802-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011830-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | KDM4E 2387/4885HRH3 58/4885CYP2D6 48/4885 |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS1, NOS2 | KDM4E 2778/4885HRH3 742/4885CYP2D6 37/4885 |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | NR1H3, NR1I3, NR1I2 | KDM4E 3442/4885HRH3 196/4885CYP2D6 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.